HIV-1	O
infection	O
induces	O
a	O
selective	O
reduction	O
in	O
STAT5	O
protein	O
expression	O
.	O

HIV-1	O
infection	O
is	O
accompanied	O
by	O
qualitative	O
and	O
quantitative	O
defects	O
in	O
CD4+	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

Loss	O
of	O
immune	O
function	O
in	O
HIV	O
patients	O
is	O
usually	O
associated	O
with	O
a	O
profound	O
dysregulation	O
of	O
cytokine	B-protein
production	O
.	O

To	O
investigate	O
whether	O
cytokine	B-protein
signaling	O
defects	O
occur	O
during	O
HIV	O
infection	O
,	O
PHA	B-cell_type
blasts	I-cell_type
from	O
healthy	O
human	O
donors	O
were	O
infected	O
with	O
two	O
strains	O
of	O
HIV-1	O
and	O
screened	O
for	O
the	O
expression	O
of	O
STAT	B-protein
proteins	I-protein
used	O
in	O
cytokine	B-protein
signaling	O
.	O

A	O
selective	O
decrease	O
in	O
STAT5B	B-protein
was	O
seen	O
8	O
days	O
after	O
infection	O
with	O
the	O
BZ167	O
dual-tropic	O
HIV	O
isolate	O
,	O
but	O
not	O
with	O
the	O
Ba-L	O
,	O
M-tropic	O
strain	O
.	O

Based	O
on	O
these	O
findings	O
,	O
purified	B-cell_type
T	I-cell_type
cells	I-cell_type
from	O
HIV-infected	O
patients	O
in	O
different	O
stages	O
of	O
disease	O
were	O
also	O
tested	O
for	O
STAT	O
expression	O
;	O
decreases	O
in	O
STAT5A	B-protein
,	O
STAT5B	B-protein
,	O
and	O
STAT1alpha	B-protein
were	O
observed	O
in	O
all	O
patients	O
.	O

The	O
reduction	O
in	O
STATs	B-protein
seen	O
in	O
vivo	O
and	O
in	O
vitro	O
after	O
HIV	O
infection	O
may	O
contribute	O
to	O
the	O
loss	O
of	O
T	B-cell_type
cell	I-cell_type
function	O
in	O
HIV	O
disease	O
.	O

VIJI	NULL
}	NULL
;	NULL
_-	NULL
___	NULL
The	NULL
Attune	NULL
``	NULL
NXT	NULL
Flow	NULL
Cytometer	NULL
system	NULL
Int	NULL
<	NULL
|	NULL
Let	NULL
's	NULL
get	NULL
to	NULL
the	NULL
science	NULL
>	NULL
~~	NULL
invitrogen	NULL
Em	NULL
The	NULL
1	NULL
,	NULL
AD	NULL
”	NULL
i'II	NULL
‘	NULL
IIfIlIJiEEIllé	NULL
‘	NULL
FIO	NULL
gy	NULL
Reduction	NULL
in	NULL
STATS	NULL
Protein	NULL
Expression	NULL
Federica	NULL
Pericle	NULL
,	NULL
Ligia	NULL
A.	NULL
Pinto	NULL
,	NULL
Stuart	NULL
Hicks	NULL
,	NULL
Robert	NULL
A.	NULL
Kirken	NULL
,	NULL
This	NULL
inf	NULL
woe	NULL
Giuseppe	NULL
Sconocchia	NULL
,	NULL
Janice	NULL
Rusnak	NULL
,	NULL
Matthew	NULL
J.	NULL
Dolan	NULL
,	NULL
Gene	NULL
M.	NULL
1s	NULL
information	NULL
1s	NULL
current	NULL
aS	NULL
_	NULL
gpearer	NULL
and	NULL
David	NULL
M.	NULL
Se	NULL
gal	NULL
of	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

J	NULL
Immunol	NULL
1998	NULL
;	NULL
160:28-31	NULL
;	NULL
;	NULL
http	NULL
:	NULL
//www	NULL
.jimmunol.org/content/160/1/28	NULL
References	NULL
_	NULL
This	NULL
article	NULL
cites	NULL
27	NULL
articles	NULL
,	NULL
8	NULL
of	NULL
which	NULL
you	NULL
can	NULL
access	NULL
for	NULL
free	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www	NULL
.jimmunol.org/content/160/1/28	NULL
.	NULL

full	NULL
#	NULL
ref-list-1	NULL
Why	NULL
The	NULL
JT	NULL
?	NULL

Submit	NULL
online	NULL
.	NULL

«	NULL
Rapid	NULL
Reviews	NULL
!	NULL

30	NULL
days*	NULL
from	NULL
submission	NULL
to	NULL
initial	NULL
decision	NULL
*	NULL
No	NULL
Triage	NULL
!	NULL

Every	NULL
submission	NULL
reviewed	NULL
by	NULL
practicing	NULL
scientists	NULL
*	NULL
Fast	NULL
Publication	NULL
!	NULL

4	NULL
weeks	NULL
from	NULL
acceptance	NULL
to	NULL
publication	NULL
*average	NULL
Subscription	NULL
_-	NULL
Information	NULL
about	NULL
subscribing	NULL
to	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
is	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//jimmunol.org/subscription	NULL
Permissions	NULL
_	NULL
Submit	NULL
copyright	NULL
permission	NULL
requests	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.aai.org/About/Publications/Jl/copyright.html	NULL
Email	NULL
Alerts	NULL
_	NULL
Receive	NULL
free	NULL
email-alerts	NULL
when	NULL
new	NULL
articles	NULL
cite	NULL
this	NULL
article	NULL
.	NULL

Sign	NULL
up	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//jimmunol.org/alerts	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
is	NULL
published	NULL
twice	NULL
each	NULL
month	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
,	NULL
Inc.	NULL
,	NULL
1451	NULL
Rockville	NULL
Pike	NULL
,	NULL
Suite	NULL
650	NULL
,	NULL
Rockville	NULL
,	NULL
MD	NULL
20852	NULL
Copyright	NULL
©	NULL
1998	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
All	NULL
rights	NULL
reserved	NULL
.	NULL

Print	NULL
ISSN	NULL
:	NULL
0022-1767	NULL
Online	NULL
ISSN	NULL
:	NULL
1550-6606	NULL
.	NULL

6107	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
810	NULL
wor	NULL
;	NULL
(	NULL
CTIDG	NULL
€	NULL
=\	NULL
a	NULL
)	NULL
Cutting	NULL
Edge	NULL
:	NULL
HIV-1	NULL
Infection	NULL
Induces	NULL
a	NULL
Selective	NULL
Reduction	NULL
in	NULL
STAT5	NULL
Protein	NULL
Expression	NULL
Federica	NULL
Pericle	NULL
,	NULL
'*	NULL
Ligia	NULL
A.	NULL
Pinto	NULL
,	NULL
'*	NULL
Stuart	NULL
Hicks	NULL
,	NULL
*	NULL
Robert	NULL
A.	NULL
Kirken	NULL
,	NULL
!	NULL

Giuseppe	NULL
Sconocchia	NULL
,	NULL
*	NULL
Janice	NULL
Rusnak	NULL
,	NULL
*	NULL
Matthew	NULL
J.	NULL
Dolan	NULL
,	NULL
*	NULL
Gene	NULL
M.	NULL
Shearer	NULL
,	NULL
*	NULL
and	NULL
David	NULL
M	NULL
.	NULL

Segal	NULL
?	NULL

*	NULL
HIV-1	NULL
infection	NULL
is	NULL
accompanied	NULL
by	NULL
qualitative	NULL
and	NULL
quantitative	NULL
defects	NULL
in	NULL
CD4	NULL
*	NULL
T	NULL
lymphocytes	NULL
.	NULL

Loss	NULL
of	NULL
immune	NULL
function	NULL
in	NULL
HIV	NULL
patients	NULL
is	NULL
usually	NULL
associated	NULL
with	NULL
a	NULL
profound	NULL
dysregu-lation	NULL
of	NULL
cytokine	NULL
production	NULL
.	NULL

To	NULL
investigate	NULL
whether	NULL
cytokine	NULL
signaling	NULL
defects	NULL
occur	NULL
during	NULL
HIV	NULL
infection	NULL
,	NULL
PHA	NULL
blasts	NULL
from	NULL
healthy	NULL
human	NULL
donors	NULL
were	NULL
infected	NULL
with	NULL
two	NULL
strains	NULL
of	NULL
HIV-1	NULL
and	NULL
screened	NULL
for	NULL
the	NULL
expression	NULL
of	NULL
STAT	NULL
proteins	NULL
used	NULL
in	NULL
cytokine	NULL
signaling	NULL
.	NULL

A	NULL
selective	NULL
decrease	NULL
in	NULL
STAT5B	NULL
was	NULL
seen	NULL
8	NULL
days	NULL
after	NULL
infection	NULL
with	NULL
the	NULL
BZ167	NULL
dual-tropic	NULL
HIV	NULL
isolate	NULL
,	NULL
but	NULL
not	NULL
with	NULL
the	NULL
Ba-L	NULL
,	NULL
M-tropic	NULL
strain	NULL
.	NULL

Based	NULL
on	NULL
these	NULL
findings	NULL
,	NULL
purified	NULL
T	NULL
cells	NULL
from	NULL
HIV-infected	NULL
patients	NULL
in	NULL
different	NULL
stages	NULL
of	NULL
disease	NULL
were	NULL
also	NULL
tested	NULL
for	NULL
STAT	NULL
expression	NULL
;	NULL
decreases	NULL
in	NULL
STAT5A	NULL
,	NULL
STAT5B	NULL
,	NULL
and	NULL
STAT1	NULL
a	NULL
were	NULL
observed	NULL
in	NULL
all	NULL
patients	NULL
.	NULL

The	NULL
reduction	NULL
in	NULL
STATs	NULL
seen	NULL
in	NULL
vivo	NULL
and	NULL
in	NULL
vitro	NULL
after	NULL
HIV	NULL
infection	NULL
may	NULL
contribute	NULL
to	NULL
the	NULL
loss	NULL
of	NULL
T	NULL
cell	NULL
function	NULL
in	NULL
HIV	NULL
disease	NULL
.	NULL

_	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
,	NULL
1998	NULL
,	NULL
160	NULL
:	NULL
286-31	NULL
.	NULL

IV	NULL
infection	NULL
is	NULL
associated	NULL
with	NULL
a	NULL
progressive	NULL
immune	NULL
H	NULL
suppression	NULL
,	NULL
characterized	NULL
by	NULL
an	NULL
early	NULL
impairment	NULL
of	NULL
CD4*	NULL
T	NULL
cell	NULL
function	NULL
and	NULL
a	NULL
later	NULL
decline	NULL
in	NULL
absolute	NULL
CD4	NULL
*	NULL
T	NULL
cell	NULL
number	NULL
(	NULL
1	NULL
,	NULL
2	NULL
)	NULL
.	NULL

Several	NULL
recent	NULL
studies	NULL
have	NULL
focused	NULL
on	NULL
the	NULL
disruption	NULL
of	NULL
signaling	NULL
pathways	NULL
in	NULL
T	NULL
cells	NULL
as	NULL
possible	NULL
causes	NULL
for	NULL
HIV-induced	NULL
immune	NULL
dysfunction	NULL
;	NULL
HIV-related	NULL
alterations	NULL
in	NULL
src	NULL
family	NULL
protein	NULL
tyrosine	NULL
kinases	NULL
(	NULL
3-7	NULL
)	NULL
,	NULL
CD45	NULL
phosphatase	NULL
(	NULL
8	NULL
)	NULL
,	NULL
protein	NULL
kinase	NULL
C	NULL
(	NULL
9	NULL
)	NULL
,	NULL
intracellular	NULL
Ca**	NULL
(	NULL
9	NULL
)	NULL
,	NULL
and	NULL
ERK-2	NULL
and	NULL
JNK	NULL
kinases	NULL
(	NULL
10	NULL
)	NULL
have	NULL
all	NULL
been	NULL
observed	NULL
.	NULL

Although	NULL
it	NULL
is	NULL
not	NULL
known	NULL
whether	NULL
these	NULL
defects	NULL
relate	NULL
to	NULL
the	NULL
syndrome	NULL
of	NULL
HIV	NULL
disease	NULL
,	NULL
it	NULL
is	NULL
*Experimental	NULL
Immunology	NULL
Branch	NULL
,	NULL
National	NULL
Cancer	NULL
Institute	NULL
,	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
,	NULL
Bethesda	NULL
,	NULL
MD	NULL
;	NULL
*Intramural	NULL
Research	NULL
Support	NULL
Program-Scientific	NULL
Applications	NULL
International	NULL
Corporation	NULL
,	NULL
Frederick	NULL
,	NULL
Laboratory	NULL
of	NULL
Molecular	NULL
Im-munoregulation	NULL
,	NULL
National	NULL
Cancer	NULL
Institute	NULL
,	NULL
Frederick	NULL
Cancer	NULL
Research	NULL
and	NULL
Development	NULL
Center	NULL
,	NULL
Frederick	NULL
,	NULL
MD	NULL
;	NULL
*HIV	NULL
Unit	NULL
,	NULL
Wilford	NULL
Hall	NULL
Medical	NULL
Center	NULL
,	NULL
Lackland	NULL
Air	NULL
Force	NULL
Base	NULL
,	NULL
TX	NULL
.	NULL

Received	NULL
for	NULL
publication	NULL
August	NULL
13	NULL
,	NULL
1997	NULL
.	NULL

Accepted	NULL
for	NULL
publication	NULL
October	NULL
28	NULL
,	NULL
1997	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
advertisement	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL
'	NULL

Contributed	NULL
equally	NULL
to	NULL
this	NULL
study	NULL
.	NULL

2	NULL
Address	NULL
correspondence	NULL
and	NULL
reprint	NULL
requests	NULL
to	NULL
Dr.	NULL
David	NULL
Segal	NULL
,	NULL
Building	NULL
10	NULL
,	NULL
Room	NULL
4B17	NULL
,	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
,	NULL
Bethesda	NULL
,	NULL
MD	NULL
20892	NULL
.	NULL

E-mail	NULL
address	NULL
:	NULL
dave_segal	NULL
@	NULL
nih.gov	NULL
Copyright	NULL
©	NULL
1998	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
likely	NULL
that	NULL
disruption	NULL
of	NULL
some	NULL
of	NULL
these	NULL
signaling	NULL
pathways	NULL
would	NULL
lead	NULL
to	NULL
losses	NULL
in	NULL
T	NULL
cell	NULL
functions	NULL
.	NULL

A	NULL
second	NULL
factor	NULL
that	NULL
could	NULL
account	NULL
for	NULL
the	NULL
impairment	NULL
of	NULL
immune	NULL
function	NULL
in	NULL
HIV-infected	NULL
individuals	NULL
is	NULL
the	NULL
profound	NULL
alteration	NULL
in	NULL
cytokine	NULL
secretion	NULL
patterns	NULL
seen	NULL
in	NULL
vivo	NULL
and	NULL
in	NULL
vitro	NULL
after	NULL
HIV	NULL
infection	NULL
(	NULL
11-13	NULL
)	NULL
.	NULL

The	NULL
cytokines	NULL
that	NULL
a	NULL
cell	NULL
secretes	NULL
typically	NULL
depend	NULL
upon	NULL
the	NULL
signals	NULL
it	NULL
receives	NULL
from	NULL
other	NULL
cytokines	NULL
in	NULL
the	NULL
medium	NULL
.	NULL

Most	NULL
cytokines	NULL
transduce	NULL
biologic	NULL
signals	NULL
from	NULL
cell	NULL
surface	NULL
receptors	NULL
to	NULL
the	NULL
nucleus	NULL
through	NULL
the	NULL
JAK-STAT	NULL
signaling	NULL
pathway	NULL
(	NULL
14-16	NULL
)	NULL
.	NULL

JAK	NULL
kinases	NULL
constitutively	NULL
associate	NULL
with	NULL
the	NULL
intracellular	NULL
domains	NULL
of	NULL
cytokine	NULL
receptors	NULL
,	NULL
and	NULL
ligation	NULL
with	NULL
cytokine	NULL
leads	NULL
to	NULL
JAK	NULL
activation	NULL
.	NULL

STAT	NULL
transcription	NULL
factors	NULL
are	NULL
recruited	NULL
to	NULL
the	NULL
activated	NULL
cytokine	NULL
receptor-JAK	NULL
kinase	NULL
complex	NULL
where	NULL
they	NULL
are	NULL
tyrosine	NULL
phosphorylated	NULL
.	NULL

The	NULL
phosphorylated	NULL
STAT	NULL
's	NULL
then	NULL
translocate	NULL
to	NULL
the	NULL
nucleus	NULL
where	NULL
they	NULL
promote	NULL
transcription	NULL
of	NULL
genes	NULL
that	NULL
control	NULL
cell	NULL
growth	NULL
,	NULL
differentiation	NULL
,	NULL
and	NULL
maintenance	NULL
of	NULL
cellular	NULL
homeostasis	NULL
.	NULL

Seven	NULL
STAT	NULL
genes	NULL
,	NULL
STATs	NULL
1-4	NULL
,	NULL
two	NULL
closely	NULL
related	NULL
isoforms	NULL
of	NULL
STAT5	NULL
,	NULL
A	NULL
and	NULL
B	NULL
,	NULL
and	NULL
STAT6	NULL
have	NULL
been	NULL
identified	NULL
to	NULL
date	NULL
(	NULL
16	NULL
,	NULL
17	NULL
)	NULL
.	NULL

Of	NULL
all	NULL
the	NULL
STATs	NULL
,	NULL
STATS	NULL
is	NULL
used	NULL
most	NULL
extensively	NULL
in	NULL
the	NULL
signaling	NULL
pathways	NULL
of	NULL
immunologi-cally	NULL
relevant	NULL
cytokines	NULL
,	NULL
including	NULL
IL-2	NULL
,	NULL
-3	NULL
,	NULL
-5	NULL
,	NULL
-7	NULL
,	NULL
-9	NULL
,	NULL
-15	NULL
,	NULL
and	NULL
granulocyte-macrophage	NULL
(	NULL
GM	NULL
)	NULL
-CSF	NULL
(	NULL
18	NULL
)	NULL
.	NULL

Recently	NULL
,	NULL
we	NULL
demonstrated	NULL
that	NULL
STATS5SA	NULL
and	NULL
STATSB	NULL
protein	NULL
and	NULL
message	NULL
were	NULL
strongly	NULL
depressed	NULL
in	NULL
tumor-bearing	NULL
mice	NULL
,	NULL
while	NULL
the	NULL
expression	NULL
of	NULL
other	NULL
members	NULL
of	NULL
the	NULL
STAT	NULL
family	NULL
were	NULL
unaltered	NULL
(	NULL
19	NULL
)	NULL
.	NULL

The	NULL
selective	NULL
reduction	NULL
of	NULL
STATS	NULL
was	NULL
associated	NULL
with	NULL
a	NULL
loss	NULL
in	NULL
T	NULL
and	NULL
B	NULL
cell	NULL
function	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
STATS	NULL
signaling	NULL
pathway	NULL
might	NULL
play	NULL
a	NULL
crucial	NULL
role	NULL
in	NULL
the	NULL
tumor-dependent	NULL
immunodeficiency	NULL
.	NULL

These	NULL
observations	NULL
raised	NULL
the	NULL
possibility	NULL
that	NULL
STAT	NULL
down-regulation	NULL
might	NULL
also	NULL
occur	NULL
in	NULL
other	NULL
immunosuppressive	NULL
conditions	NULL
.	NULL

Therefore	NULL
,	NULL
in	NULL
the	NULL
current	NULL
report	NULL
we	NULL
studied	NULL
the	NULL
expression	NULL
of	NULL
STAT	NULL
proteins	NULL
in	NULL
T	NULL
cells	NULL
from	NULL
normal	NULL
donors	NULL
following	NULL
in	NULL
vitro	NULL
infection	NULL
with	NULL
HIV-1	NULL
and	NULL
in	NULL
T	NULL
cells	NULL
from	NULL
HIV-infected	NULL
patients	NULL
.	NULL

We	NULL
show	NULL
that	NULL
in	NULL
vitro	NULL
HIV-1	NULL
infection	NULL
can	NULL
directly	NULL
induce	NULL
a	NULL
selective	NULL
down-modulation	NULL
of	NULL
STAT5B	NULL
and	NULL
that	NULL
T	NULL
cells	NULL
from	NULL
HIV-infected	NULL
individuals	NULL
have	NULL
decreased	NULL
expression	NULL
of	NULL
both	NULL
STATSA	NULL
and	NULL
-B	NULL
.	NULL

Materials	NULL
and	NULL
Methods	NULL
Cells	NULL
PBMC	NULL
were	NULL
prepared	NULL
from	NULL
buffy	NULL
coats	NULL
from	NULL
normal	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
Blood	NULL
Bank	NULL
donors	NULL
by	NULL
Ficoll/Hypaque	NULL
separation	NULL
(	NULL
20	NULL
)	NULL
.	NULL

PBL	NULL
from	NULL
HIV-infected	NULL
patients	NULL
were	NULL
isolated	NULL
by	NULL
Ficoll-Hypaque	NULL
separation	NULL
and	NULL
plastic	NULL
adherence	NULL
(	NULL
21	NULL
)	NULL
.	NULL

CD3	NULL
*	NULL
T	NULL
cells	NULL
were	NULL
enriched	NULL
from	NULL
PBL	NULL
by	NULL
negative	NULL
selection	NULL
using	NULL
a	NULL
mAb	NULL
mixture	NULL
plus	NULL
complement	NULL
(	NULL
Lymphokwik	NULL
,	NULL
One	NULL
0022-1	NULL
6107	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
810	NULL
wor	NULL
;	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
WR	NULL
-~	NULL
Wege	NULL
)	NULL
-~	NULL
AUK	NULL
-~	NULL
wt	NULL
wo	NULL
»	NULL
``	NULL
,	NULL
-o-	NULL
STATSA	NULL
Mu	NULL
(	NULL
R	NULL
-m	NULL
HIV-1	NULL
:	NULL
_-	NULL
+	NULL
==	NULL
+	NULL
Day	NULL
3	NULL
Day	NULL
8	NULL
FIGURE	NULL
1	NULL
.	NULL

HIV-1-infected	NULL
PBMC	NULL
show	NULL
a	NULL
selective	NULL
reduction	NULL
of	NULL
STATSB	NULL
expression	NULL
.	NULL

Cell	NULL
lysates	NULL
from	NULL
3-	NULL
and	NULL
8-day	NULL
cultures	NULL
of	NULL
uninfected	NULL
and	NULL
HIV-15	NULL
;	NULL
7	NULL
;	NULL
,47-infected	NULL
PHA	NULL
blasts	NULL
were	NULL
immunoprecipitated	NULL
and	NULL
probed	NULL
for	NULL
the	NULL
indicated	NULL
STAT	NULL
using	NULL
the	NULL
same	NULL
Ab	NULL
for	NULL
both	NULL
precipitation	NULL
and	NULL
Western	NULL
blotting	NULL
.	NULL

Results	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
experiments	NULL
.	NULL

Lambda	NULL
Inc.	NULL
,	NULL
Los	NULL
Angeles	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Patients	NULL
were	NULL
classified	NULL
according	NULL
to	NULL
the	NULL
Walter	NULL
Reed	NULL
guidelines	NULL
for	NULL
the	NULL
staging	NULL
of	NULL
HIV-infected	NULL
individuals	NULL
(	NULL
22	NULL
)	NULL
.	NULL

The	NULL
use	NULL
of	NULL
human	NULL
blood	NULL
samples	NULL
in	NULL
these	NULL
studies	NULL
was	NULL
approved	NULL
by	NULL
the	NULL
Institutional	NULL
Review	NULL
Boards	NULL
of	NULL
both	NULL
institutions	NULL
.	NULL

Viral	NULL
stocks	NULL
Two	NULL
HIV-1	NULL
isolates	NULL
were	NULL
used	NULL
in	NULL
this	NULL
study	NULL
.	NULL

HIV-lg	NULL
;	NULL
;	NULL
4	NULL
;	NULL
was	NULL
grown	NULL
in	NULL
human	NULL
PHA	NULL
blasts	NULL
,	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
23	NULL
)	NULL
.	NULL

4	NULL
,	NULL
was	NULL
grown	NULL
in	NULL
monocyte-derived	NULL
macrophages	NULL
.	NULL

Cell-free	NULL
supernatants	NULL
were	NULL
titered	NULL
for	NULL
p24	NULL
core	NULL
Ag	NULL
by	NULL
ELISA	NULL
(	NULL
AIDS	NULL
Vaccine	NULL
Program	NULL
,	NULL
NCI	NULL
,	NULL
Frederick	NULL
,	NULL
MD	NULL
)	NULL
.	NULL

HIV	NULL
infection	NULL
PBMC	NULL
(	NULL
2	NULL
X	NULL
10¢/ml	NULL
)	NULL
were	NULL
stimulated	NULL
with	NULL
2	NULL
ug/ml	NULL
PHA	NULL
(	NULL
Sigma	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
for	NULL
3	NULL
days	NULL
at	NULL
37°C	NULL
,	NULL
and	NULL
washed	NULL
twice	NULL
.	NULL

PHA	NULL
blasts	NULL
(	NULL
10	NULL
``	NULL
/sample	NULL
)	NULL
were	NULL
incubated	NULL
for	NULL
2	NULL
h	NULL
with	NULL
HIV-1§7	NULL
;	NULL
,4	NULL
,	NULL
or	NULL
HIV-14	NULL
,	NULL
,	NULL
,	NULL
(	NULL
172	NULL
and	NULL
570	NULL
tissue	NULL
culture	NULL
IDs	NULL
,	NULL
,	NULL
respectively	NULL
)	NULL
and	NULL
washed	NULL
three	NULL
times	NULL
.	NULL

Infected	NULL
cells	NULL
(	NULL
1	NULL
X	NULL
10°/ml	NULL
)	NULL
were	NULL
incubated	NULL
3	NULL
or	NULL
8	NULL
days	NULL
in	NULL
medium	NULL
supplemented	NULL
with	NULL
10	NULL
U/ml	NULL
of	NULL
recombinant	NULL
IL-2	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
,	NULL
Indianapolis	NULL
,	NULL
IN	NULL
)	NULL
.	NULL

Medium	NULL
in	NULL
the	NULL
8-day	NULL
cultures	NULL
was	NULL
replaced	NULL
4	NULL
days	NULL
after	NULL
infection	NULL
.	NULL

HIV-1	NULL
infection	NULL
was	NULL
followed	NULL
by	NULL
ELISA	NULL
for	NULL
HIV-1	NULL
p24	NULL
.	NULL

Immunoprecipitations	NULL
The	NULL
immunoprecipitation	NULL
procedure	NULL
has	NULL
been	NULL
described	NULL
previously	NULL
(	NULL
19	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
5	NULL
X	NULL
10°	NULL
cells/group	NULL
were	NULL
incubated	NULL
for	NULL
1	NULL
h	NULL
at	NULL
4°C	NULL
in	NULL
Triton	NULL
X-100	NULL
(	NULL
1	NULL
%	NULL
)	NULL
lysing	NULL
buffer	NULL
and	NULL
spun	NULL
.	NULL

Supernatants	NULL
were	NULL
incubated	NULL
with	NULL
anti-STAT	NULL
polyclonal	NULL
Ab	NULL
and	NULL
adsorbed	NULL
with	NULL
protein	NULL
A-Sepharose	NULL
beads	NULL
(	NULL
Pharmacia	NULL
,	NULL
Piscataway	NULL
,	NULL
NJ	NULL
)	NULL
.	NULL

Adsorbed	NULL
proteins	NULL
were	NULL
analyzed	NULL
by	NULL
SDS-PAGE	NULL
under	NULL
reducing	NULL
conditions	NULL
on	NULL
a	NULL
7.5	NULL
%	NULL
homogeneous	NULL
PhastGel	NULL
(	NULL
Pharmacia	NULL
)	NULL
followed	NULL
by	NULL
Western	NULL
blotting	NULL
with	NULL
the	NULL
same	NULL
Ab	NULL
used	NULL
for	NULL
immunoprecipitation	NULL
.	NULL

Proteins	NULL
were	NULL
detected	NULL
by	NULL
enhanced	NULL
chemiluminescence	NULL
.	NULL

Results	NULL
In	NULL
vitro	NULL
HIV-1	NULL
infection	NULL
reduces	NULL
STATS	NULL
expression	NULL
We	NULL
previously	NULL
showed	NULL
that	NULL
immunosuppression	NULL
in	NULL
tumor	NULL
bearing	NULL
mice	NULL
was	NULL
accompanied	NULL
by	NULL
a	NULL
loss	NULL
in	NULL
STATS	NULL
expression	NULL
(	NULL
19	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
HIV	NULL
infection	NULL
would	NULL
elicit	NULL
a	NULL
similar	NULL
effect	NULL
,	NULL
PHA	NULL
blasts	NULL
from	NULL
healthy	NULL
,	NULL
HIV-negative	NULL
donors	NULL
were	NULL
infected	NULL
with	NULL
the	NULL
primary	NULL
HIV-1	NULL
isolate	NULL
,	NULL
BZ167	NULL
,	NULL
and	NULL
STAT	NULL
expression	NULL
was	NULL
assessed	NULL
by	NULL
immunoprecipitation	NULL
and	NULL
Western	NULL
blotting	NULL
3	NULL
and	NULL
8	NULL
days	NULL
after	NULL
infection	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

By	NULL
day	NULL
8	NULL
,	NULL
when	NULL
viral	NULL
replication	NULL
was	NULL
well	NULL
advanced	NULL
(	NULL
Table	NULL
I	NULL
)	NULL
,	NULL
STAT5B	NULL
expression	NULL
was	NULL
strikingly	NULL
reduced	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
STAT	NULL
's	NULL
1	NULL
,	NULL
2	NULL
,	NULL
3	NULL
and	NULL
5A	NULL
were	NULL
not	NULL
significantly	NULL
altered	NULL
.	NULL

29	NULL
Table	NULL
I.	NULL
HIV-1	NULL
p24	NULL
Ag	NULL
production	NULL
by	NULL
HIV-1-infected	NULL
PHA	NULL
blasts	NULL
p24	NULL
Production	NULL
(	NULL
ng/m	NULL
!	NULL
)	NULL

HIV-1	NULL
Viral	NULL
Strain	NULL
Day	NULL
3	NULL
Day	NULL
8	NULL
BZ167	NULL
78.1	NULL
£	NULL
41.4	NULL
(	NULL
5	NULL
)	NULL
°	NULL
Ba-L	NULL
19.1	NULL
+	NULL
21.9	NULL
(	NULL
2	NULL
)	NULL
563.1	NULL
+	NULL
364.8	NULL
(	NULL
5	NULL
)	NULL
50.7	NULL
+	NULL
52.2	NULL
(	NULL
6	NULL
)	NULL
*	NULL
Mean	NULL
+	NULL
SD	NULL
(	NULL
number	NULL
of	NULL
samples	NULL
)	NULL
.	NULL

Each	NULL
sample	NULL
represents	NULL
a	NULL
separate	NULL
experiment	NULL
using	NULL
cells	NULL
from	NULL
a	NULL
different	NULL
donor	NULL
.	NULL

No	NULL
loss	NULL
in	NULL
STATS5B	NULL
was	NULL
observed	NULL
3	NULL
days	NULL
after	NULL
infection	NULL
when	NULL
viral	NULL
replication	NULL
was	NULL
significantly	NULL
less	NULL
,	NULL
indicating	NULL
that	NULL
STAT5B	NULL
modulation	NULL
occurred	NULL
late	NULL
in	NULL
the	NULL
infection	NULL
cycle	NULL
.	NULL

Because	NULL
gp120	NULL
and	NULL
tat	NULL
proteins	NULL
have	NULL
been	NULL
found	NULL
to	NULL
affect	NULL
immune	NULL
function	NULL
(	NULL
24-27	NULL
)	NULL
,	NULL
we	NULL
tested	NULL
whether	NULL
culturing	NULL
PHA	NULL
blasts	NULL
with	NULL
either	NULL
of	NULL
these	NULL
HIV-1	NULL
proteins	NULL
would	NULL
alter	NULL
STATSA	NULL
or	NULL
B	NULL
expression	NULL
.	NULL

A	NULL
mixture	NULL
of	NULL
recombinant	NULL
gp120	NULL
and	NULL
tat	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
STATSA	NULL
or	NULL
B	NULL
expres-sion	NULL
,	NULL
and	NULL
similar	NULL
negative	NULL
results	NULL
were	NULL
obtained	NULL
when	NULL
the	NULL
cells	NULL
were	NULL
cultured	NULL
for	NULL
3	NULL
or	NULL
8	NULL
days	NULL
with	NULL
either	NULL
tat	NULL
or	NULL
gp120	NULL
alone	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Preferential	NULL
down-regulation	NULL
of	NULL
STAT5B	NULL
by	NULL
HIV-1	NULL
The	NULL
capacity	NULL
of	NULL
the	NULL
dual-tropic	NULL
HIV-1	NULL
strain	NULL
BZ167	NULL
to	NULL
down-mod-ulate	NULL
STATS5B	NULL
was	NULL
compared	NULL
with	NULL
that	NULL
of	NULL
the	NULL
M-tropic	NULL
strain	NULL
Ba-L.	NULL
HIV-l1py47	NULL
isolate	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
)	NULL
,	NULL
which	NULL
uses	NULL
predominantly	NULL
CXCR4	NULL
and	NULL
CCR3	NULL
coreceptors	NULL
(	NULL
D.	NULL
Cohen	NULL
,	NULL
unpublished	NULL
observa-tion	NULL
)	NULL
,	NULL
markedly	NULL
decreased	NULL
STATS5B	NULL
expression	NULL
but	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
STAT1	NULL
or	NULL
STATS5A	NULL
,	NULL
consistent	NULL
with	NULL
the	NULL
results	NULL
presented	NULL
above	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
the	NULL
Ba-L	NULL
M-tropic	NULL
HIV-1	NULL
strain	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
,	NULL
which	NULL
uses	NULL
primarily	NULL
CCR5	NULL
as	NULL
coreceptor	NULL
(	NULL
28	NULL
)	NULL
,	NULL
had	NULL
little	NULL
effect	NULL
on	NULL
the	NULL
expression	NULL
of	NULL
any	NULL
of	NULL
the	NULL
three	NULL
STATs	NULL
examined	NULL
.	NULL

HIV-1py457	NULL
was	NULL
significantly	NULL
more	NULL
virulent	NULL
than	NULL
HIV-1	NULL
»	NULL
,	NULL
,	NULL
,	NULL
,	NULL
(	NULL
Table	NULL
I	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
difference	NULL
between	NULL
the	NULL
two	NULL
strains	NULL
in	NULL
blocking	NULL
STATS5B	NULL
expression	NULL
was	NULL
due	NULL
to	NULL
differences	NULL
in	NULL
their	NULL
abilities	NULL
to	NULL
infect	NULL
the	NULL
cells	NULL
.	NULL

STAT5A	NULL
and	NULL
-B	NULL
are	NULL
reduced	NULL
in	NULL
T	NULL
cells	NULL
from	NULL
HIV-1-infected	NULL
individuals	NULL
The	NULL
capacity	NULL
of	NULL
HIV-ly	NULL
;	NULL
47	NULL
to	NULL
decrease	NULL
STAT5B	NULL
expression	NULL
in	NULL
infected	NULL
PHA	NULL
blasts	NULL
raised	NULL
the	NULL
possibility	NULL
that	NULL
STAT	NULL
levels	NULL
might	NULL
also	NULL
be	NULL
reduced	NULL
in	NULL
the	NULL
T	NULL
cells	NULL
of	NULL
HIV-1-infected	NULL
donors	NULL
.	NULL

Purified	NULL
T	NULL
cells	NULL
from	NULL
5	NULL
HIV-positive	NULL
patients	NULL
exhibiting	NULL
a	NULL
range	NULL
of	NULL
CD4	NULL
counts	NULL
(	NULL
Table	NULL
II	NULL
)	NULL
were	NULL
examined	NULL
for	NULL
the	NULL
levels	NULL
of	NULL
expression	NULL
of	NULL
STATS	NULL
proteins	NULL
.	NULL

As	NULL
seen	NULL
in	NULL
Figure	NULL
3	NULL
,	NULL
both	NULL
STATSA	NULL
and	NULL
STATS5B	NULL
were	NULL
markedly	NULL
reduced	NULL
in	NULL
all	NULL
5	NULL
of	NULL
the	NULL
HIV-positive	NULL
patients	NULL
(	NULL
P1	NULL
through	NULL
P5	NULL
)	NULL
,	NULL
as	NULL
compared	NULL
with	NULL
2	NULL
HIV-negative	NULL
(	NULL
N1	NULL
and	NULL
N2	NULL
)	NULL
control	NULL
donors	NULL
studied	NULL
simultaneously	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
STAT3	NULL
,	NULL
STAT6	NULL
,	NULL
and	NULL
the	NULL
lower	NULL
m.w	NULL
.	NULL

splice	NULL
variant	NULL
of	NULL
STAT1	NULL
(	NULL
STAT1B	NULL
)	NULL
showed	NULL
near	NULL
normal	NULL
levels	NULL
of	NULL
protein	NULL
expression	NULL
in	NULL
all	NULL
donors	NULL
.	NULL

Interest-ingly	NULL
,	NULL
the	NULL
higher	NULL
m.w	NULL
.	NULL

variant	NULL
,	NULL
STAT1	NULL
«	NULL
,	NULL
appeared	NULL
to	NULL
be	NULL
absent	NULL
in	NULL
the	NULL
cells	NULL
from	NULL
the	NULL
infected	NULL
patients	NULL
.	NULL

No	NULL
quantitative	NULL
correlation	NULL
between	NULL
the	NULL
reduction	NULL
in	NULL
STAT	NULL
protein	NULL
and	NULL
either	NULL
the	NULL
stage	NULL
of	NULL
the	NULL
disease	NULL
or	NULL
therapy	NULL
was	NULL
observed	NULL
in	NULL
this	NULL
small	NULL
group	NULL
of	NULL
patients	NULL
.	NULL

Further	NULL
studies	NULL
in	NULL
an	NULL
extended	NULL
group	NULL
of	NULL
patients	NULL
will	NULL
be	NULL
necessary	NULL
to	NULL
elucidate	NULL
the	NULL
relationship	NULL
between	NULL
clinical	NULL
characteristics	NULL
and	NULL
alteration	NULL
in	NULL
STAT	NULL
expression	NULL
.	NULL

Reduced	NULL
expression	NULL
of	NULL
STATS5A	NULL
,	NULL
STAT5B	NULL
,	NULL
and	NULL
STAT1a	NULL
in	NULL
patients	NULL
'	NULL
T	NULL
cells	NULL
differed	NULL
from	NULL
in	NULL
vitro	NULL
HIV-1-infected	NULL
cultures	NULL
in	NULL
which	NULL
the	NULL
reduction	NULL
was	NULL
limited	NULL
to	NULL
STAT5B	NULL
.	NULL

Discussion	NULL
In	NULL
the	NULL
current	NULL
study	NULL
we	NULL
demonstrated	NULL
that	NULL
in	NULL
vitro	NULL
infection	NULL
of	NULL
PBMC	NULL
or	NULL
in	NULL
vivo	NULL
infection	NULL
of	NULL
patients	NULL
with	NULL
HIV-1	NULL
is	NULL
accompanied	NULL
6107	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
810	NULL
wor	NULL
;	NULL
30	NULL
lll	NULL
3	NULL
-	NULL
4	NULL
&	NULL
#	NULL
#	NULL
ue	NULL
-G-	NULL
STATi	NULL
Us	NULL
**	NULL
as	NULL
use	NULL
-G-	NULL
STAT5A	NULL
-a-	NULL
STAT5B	NULL
HIV-1	NULL
;	NULL
)	NULL
-*	NULL
)	NULL
Edt	NULL
|||	NULL
ad	NULL
||	NULL
BZ167	NULL
~	NULL
+	NULL
im	NULL
+	NULL
B	NULL
12	NULL
3	NULL
|	NULL
4	NULL
wm	NULL
,	NULL
-	NULL
#	NULL
9.	NULL
an	NULL
Z4	NULL
--	NULL
STATi	NULL
w-	NULL
»	NULL
-	NULL
gomeme	NULL
-	NULL
wn	NULL
wih	NULL
ws	NULL
-G4-	NULL
STAT5A	NULL
was	NULL
Wie	NULL
--	NULL
STATSB	NULL
NIV-1	NULL
;	NULL
)	NULL
'	NULL
EES	NULL
E	NULL
)	NULL
)	NULL
hard	NULL
Bat-1	NULL
|	NULL
T.	NULL
F	NULL
n	NULL
|	NULL
5	NULL
FIGURE	NULL
2	NULL
.	NULL

Decreased	NULL
STATSB	NULL
expression	NULL
in	NULL
HIV-1	NULL
$	NULL
;	NULL
,47-	NULL
but	NULL
not	NULL
Ba-L-infected	NULL
PHA	NULL
blasts	NULL
.	NULL

PHA	NULL
blasts	NULL
from	NULL
four	NULL
separate	NULL
donors	NULL
were	NULL
infected	NULL
,	NULL
cultured	NULL
for	NULL
8	NULL
days	NULL
,	NULL
and	NULL
tested	NULL
for	NULL
expression	NULL
of	NULL
the	NULL
indicated	NULL
STAT	NULL
.	NULL

Lanes	NULL
1	NULL
and	NULL
3	NULL
,	NULL
uninfected	NULL
cells	NULL
;	NULL
lanes	NULL
2	NULL
and	NULL
4	NULL
,	NULL
cells	NULL
infected	NULL
with	NULL
HIV-1	NULL
57147	NULL
(	NULL
A	NULL
)	NULL
or	NULL
with	NULL
;	NULL
(	NULL
B	NULL
)	NULL
.	NULL

These	NULL
data	NULL
have	NULL
been	NULL
confirmed	NULL
in	NULL
three	NULL
separate	NULL
experiments	NULL
.	NULL

Table	NULL
II	NULL
.	NULL

-	NULL
Clinical	NULL
status	NULL
of	NULL
patients	NULL
examined	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
Patient	NULL
CD4*	NULL
Clinical	NULL
Anti-Viral	NULL
No	NULL
.	NULL

T	NULL
Cells/mm*	NULL
Stage	NULL
``	NULL
Therapy®	NULL
1	NULL
266	NULL
WRS	NULL
D4T	NULL
,	NULL
3TC	NULL
2	NULL
300	NULL
WRG	NULL
DDI	NULL
,	NULL
D4T	NULL
,	NULL
IND	NULL
3	NULL
449	NULL
WR4	NULL
D4T	NULL
,	NULL
3TC	NULL
4	NULL
311	NULL
WR2	NULL
None	NULL
5	NULL
497	NULL
WR1	NULL
None	NULL
*	NULL
WR	NULL
,	NULL
Walter	NULL
Reed	NULL
stage	NULL
.	NULL

®	NULL
DAT	NULL
,	NULL
stavudine	NULL
;	NULL
3TC	NULL
,	NULL
lamivudine	NULL
;	NULL
DDI	NULL
,	NULL
didanosine	NULL
;	NULL
IND	NULL
,	NULL
indinavir	NULL
.	NULL

by	NULL
a	NULL
marked	NULL
decrease	NULL
in	NULL
the	NULL
expression	NULL
STAT5	NULL
,	NULL
a	NULL
transcription	NULL
factor	NULL
used	NULL
in	NULL
the	NULL
transduction	NULL
of	NULL
intracellular	NULL
signals	NULL
by	NULL
a	NULL
wide	NULL
variety	NULL
of	NULL
cytokine	NULL
receptors	NULL
(	NULL
14	NULL
)	NULL
.	NULL

In	NULL
vitro	NULL
infection	NULL
of	NULL
PHA	NULL
blasts	NULL
from	NULL
HIV-negative	NULL
donors	NULL
with	NULL
the	NULL
dual-tropic	NULL
HIV-1	NULL
strain	NULL
BZ167	NULL
induced	NULL
a	NULL
selective	NULL
loss	NULL
of	NULL
STAT5B	NULL
protein	NULL
.	NULL

The	NULL
specificity	NULL
of	NULL
this	NULL
response	NULL
was	NULL
striking	NULL
because	NULL
it	NULL
was	NULL
not	NULL
observed	NULL
with	NULL
any	NULL
of	NULL
the	NULL
other	NULL
STAT	NULL
proteins	NULL
examined	NULL
,	NULL
including	NULL
the	NULL
highly	NULL
homol-ogous	NULL
STATSA	NULL
isoform	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
)	NULL
.	NULL

The	NULL
loss	NULL
in	NULL
STATS5B	NULL
protein	NULL
may	NULL
have	NULL
been	NULL
due	NULL
to	NULL
a	NULL
decrease	NULL
in	NULL
its	NULL
rate	NULL
of	NULL
synthesis	NULL
or	NULL
an	NULL
increase	NULL
in	NULL
its	NULL
degradation	NULL
rate	NULL
,	NULL
but	NULL
it	NULL
was	NULL
not	NULL
due	NULL
to	NULL
its	NULL
translo-cation	NULL
to	NULL
the	NULL
nucleus	NULL
since	NULL
the	NULL
lysis	NULL
conditions	NULL
used	NULL
in	NULL
our	NULL
experiments	NULL
released	NULL
both	NULL
cytoplasmic	NULL
and	NULL
nuclear	NULL
STAT	NULL
's	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
down-regulation	NULL
of	NULL
STATS5B	NULL
was	NULL
observed	NULL
only	NULL
late	NULL
after	NULL
infection	NULL
with	NULL
the	NULL
BZ167	NULL
strain	NULL
,	NULL
and	NULL
in	NULL
cultures	NULL
that	NULL
were	NULL
producing	NULL
a	NULL
high	NULL
amount	NULL
of	NULL
virus	NULL
,	NULL
as	NULL
measured	NULL
by	NULL
p24	NULL
release	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
Table	NULL
I	NULL
)	NULL
.	NULL

Infection	NULL
of	NULL
PHA	NULL
blasts	NULL
with	NULL
the	NULL
M-tropic	NULL
strain	NULL
;	NULL
,	NULL
failed	NULL
to	NULL
decrease	NULL
STATS5B	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
,	NULL
possibly	NULL
because	NULL
the	NULL
level	NULL
of	NULL
CUTTING	NULL
EDGE	NULL
.	NULL

&	NULL
a	NULL
e	NULL
.	NULL

-all	NULL
-	NULL
STATA	NULL
``	NULL
'goo	NULL
'	NULL
-all	NULL
-	NULL
STAT3	NULL
s	NULL
wee	NULL
-il	NULL
-	NULL
STAT5A	NULL
-ll-STAT5B	NULL
am	NULL
hal	NULL
``	NULL
l0	NULL
a	NULL
.	NULL

-all	NULL
-	NULL
STAT6	NULL
L_	NULL
L_	NULL
)	NULL
L_	NULL
)	NULL
L_	NULL
)	NULL
L_	NULL
L	NULL
_4	NULL
Donors	NULL
:	NULL
N1	NULL
P1	NULL
P2	NULL
P3	NULL
P4	NULL
P5	NULL
N2	NULL
FIGURE	NULL
3	NULL
.	NULL

Reduced	NULL
expression	NULL
of	NULL
STAT1	NULL
«	NULL
,	NULL
STAT5A	NULL
and	NULL
STATSB	NULL
in	NULL
T	NULL
cells	NULL
from	NULL
HIV*	NULL
patients	NULL
.	NULL

Purified	NULL
T	NULL
cells	NULL
from	NULL
two	NULL
healthy	NULL
,	NULL
HIV-negative	NULL
(	NULL
N	NULL
)	NULL
donors	NULL
and	NULL
five	NULL
HIV-infected	NULL
patients	NULL
(	NULL
P1-P5	NULL
)	NULL
were	NULL
analyzed	NULL
for	NULL
STAT1	NULL
,	NULL
-3	NULL
,	NULL
-5A	NULL
,	NULL
-5B	NULL
,	NULL
and	NULL
-6	NULL
expression	NULL
.	NULL

Patients	NULL
'	NULL
disease	NULL
status	NULL
are	NULL
indicated	NULL
in	NULL
Table	NULL
II	NULL
.	NULL

Shown	NULL
are	NULL
Western	NULL
blots	NULL
of	NULL
immuno-precipitates	NULL
using	NULL
Abs	NULL
against	NULL
the	NULL
indicated	NULL
STATs	NULL
.	NULL

infection	NULL
was	NULL
much	NULL
lower	NULL
with	NULL
this	NULL
isolate	NULL
than	NULL
with	NULL
(	NULL
Table	NULL
I	NULL
)	NULL
.	NULL

Most	NULL
sexual	NULL
transmissions	NULL
of	NULL
HIV-1	NULL
are	NULL
caused	NULL
by	NULL
M-tropic	NULL
viruses	NULL
(	NULL
29	NULL
,	NULL
30	NULL
)	NULL
;	NULL
therefore	NULL
,	NULL
the	NULL
down-regulation	NULL
of	NULL
STATSB	NULL
associated	NULL
with	NULL
the	NULL
direct	NULL
infection	NULL
of	NULL
T	NULL
cells	NULL
would	NULL
likely	NULL
occur	NULL
in	NULL
infected	NULL
individuals	NULL
only	NULL
after	NULL
the	NULL
virus	NULL
evolved	NULL
in	NULL
vivo	NULL
into	NULL
a	NULL
T-tropic	NULL
form	NULL
.	NULL

The	NULL
decrease	NULL
in	NULL
STATS5	NULL
and	NULL
STAT1a	NULL
expression	NULL
in	NULL
purified	NULL
T	NULL
cells	NULL
from	NULL
HIV	NULL
infected	NULL
patients	NULL
was	NULL
remarkable	NULL
because	NULL
it	NULL
occurred	NULL
in	NULL
all	NULL
five	NULL
patients	NULL
examined	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
,	NULL
although	NULL
these	NULL
patients	NULL
differed	NULL
with	NULL
respect	NULL
to	NULL
their	NULL
disease	NULL
stages	NULL
and	NULL
CD4	NULL
*	NULL
T	NULL
cell	NULL
counts	NULL
(	NULL
Table	NULL
II	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
in	NULL
vitro	NULL
infection	NULL
of	NULL
PHA	NULL
blasts	NULL
,	NULL
STATS5A	NULL
,	NULL
STATS5B	NULL
and	NULL
STAT1a	NULL
were	NULL
all	NULL
reduced	NULL
in	NULL
patients	NULL
'	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
loss	NULL
of	NULL
these	NULL
STATs	NULL
was	NULL
selective	NULL
because	NULL
no	NULL
consistent	NULL
change	NULL
was	NULL
detected	NULL
in	NULL
the	NULL
expression	NULL
of	NULL
STAT1B	NULL
,	NULL
STAT3	NULL
,	NULL
and	NULL
STAT6	NULL
.	NULL

Our	NULL
preliminary	NULL
finding	NULL
that	NULL
STAT1	NULL
«	NULL
but	NULL
not	NULL
-	NULL
is	NULL
lost	NULL
in	NULL
HIV	NULL
*	NULL
patients	NULL
could	NULL
have	NULL
profound	NULL
immunologic	NULL
consequences	NULL
because	NULL
the	NULL
a	NULL
and	NULL
B	NULL
forms	NULL
of	NULL
STAT1	NULL
are	NULL
splice	NULL
variants	NULL
,	NULL
with	NULL
STAT1B	NULL
acting	NULL
as	NULL
a	NULL
dominant	NULL
negative	NULL
.	NULL

Thus	NULL
the	NULL
loss	NULL
of	NULL
the	NULL
a	NULL
form	NULL
of	NULL
STAT1	NULL
could	NULL
lead	NULL
to	NULL
abrogation	NULL
of	NULL
STAT1	NULL
function	NULL
,	NULL
which	NULL
in	NULL
deficient	NULL
mice	NULL
produces	NULL
impaired	NULL
innate	NULL
immunity	NULL
to	NULL
viral	NULL
infections	NULL
(	NULL
15	NULL
)	NULL
.	NULL

Since	NULL
most	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
are	NULL
not	NULL
infected	NULL
in	NULL
HIV	NULL
*	NULL
patients	NULL
(	NULL
31	NULL
)	NULL
,	NULL
it	NULL
is	NULL
unlikely	NULL
that	NULL
the	NULL
loss	NULL
in	NULL
STATS	NULL
and	NULL
STAT1a	NULL
seen	NULL
in	NULL
lysates	NULL
from	NULL
patients	NULL
'	NULL
T	NULL
cells	NULL
was	NULL
due	NULL
to	NULL
a	NULL
direct	NULL
effect	NULL
of	NULL
the	NULL
virus	NULL
on	NULL
STAT	NULL
expression	NULL
.	NULL

A	NULL
more	NULL
likely	NULL
mechanism	NULL
is	NULL
that	NULL
HIV-1	NULL
induced	NULL
the	NULL
secretion	NULL
of	NULL
one	NULL
or	NULL
more	NULL
factors	NULL
that	NULL
resulted	NULL
in	NULL
STAT	NULL
down-regulation	NULL
.	NULL

Decreased	NULL
STATS	NULL
expression	NULL
has	NULL
now	NULL
been	NULL
observed	NULL
in	NULL
two	NULL
unrelated	NULL
diseases	NULL
that	NULL
cause	NULL
immunosuppression	NULL
,	NULL
HIV	NULL
disease	NULL
in	NULL
humans	NULL
and	NULL
experimentally	NULL
induced	NULL
mammary	NULL
carcinoma	NULL
in	NULL
mice	NULL
(	NULL
19	NULL
)	NULL
.	NULL

The	NULL
role	NULL
that	NULL
STATS	NULL
plays	NULL
in	NULL
the	NULL
impairment	NULL
of	NULL
immune	NULL
function	NULL
in	NULL
these	NULL
diseases	NULL
is	NULL
not	NULL
known	NULL
.	NULL

However	NULL
,	NULL
because	NULL
STATS	NULL
has	NULL
a	NULL
broad	NULL
spectrum	NULL
of	NULL
cytokine	NULL
usage	NULL
,	NULL
its	NULL
loss	NULL
would	NULL
be	NULL
expected	NULL
to	NULL
strongly	NULL
influence	NULL
the	NULL
immune	NULL
system	NULL
.	NULL

The	NULL
present	NULL
study	NULL
is	NULL
the	NULL
first	NULL
to	NULL
suggest	NULL
that	NULL
regulation	NULL
of	NULL
STATS5	NULL
may	NULL
be	NULL
involved	NULL
in	NULL
modulating	NULL
cytokine	NULL
profiles	NULL
and	NULL
immune	NULL
function	NULL
in	NULL
HIV-infected	NULL
patients	NULL
.	NULL

This	NULL
study	NULL
,	NULL
as	NULL
well	NULL
as	NULL
the	NULL
previous	NULL
report	NULL
demonstrating	NULL
STATS5	NULL
decreases	NULL
in	NULL
tumor-bearing	NULL
mice	NULL
(	NULL
19	NULL
)	NULL
,	NULL
suggests	NULL
that	NULL
the	NULL
regulation	NULL
of	NULL
STAT	NULL
signaling	NULL
pathways	NULL
may	NULL
provide	NULL
a	NULL
molecular	NULL
mechanism	NULL
that	NULL
the	NULL
immune	NULL
system	NULL
uses	NULL
to	NULL
control	NULL
its	NULL
level	NULL
of	NULL
activity	NULL
.	NULL

References	NULL
1	NULL
.	NULL

Miedema	NULL
,	NULL
F.	NULL
,	NULL
A.	NULL
J.	NULL
Petit	NULL
,	NULL
F.	NULL
G.	NULL
Terpstra	NULL
,	NULL
J.	NULL
K.	NULL
Schattenkerk	NULL
,	NULL
F.	NULL
de	NULL
Wolf	NULL
,	NULL
B.	NULL
J.	NULL
Al	NULL
,	NULL
M.	NULL
Roos	NULL
,	NULL
J.	NULL
M.	NULL
Lange	NULL
,	NULL
S.	NULL
A.	NULL
Danner	NULL
,	NULL
and	NULL
J.	NULL
Goudsmit	NULL
.	NULL

1988	NULL
.	NULL

Immunological	NULL
abnormalities	NULL
in	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
(	NULL
HIV	NULL
)	NULL
-infected	NULL
asymptomatic	NULL
6107	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
810	NULL
wor	NULL
;	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17.	NULL
homosexual	NULL
men	NULL
:	NULL
HIV	NULL
affects	NULL
the	NULL
immune	NULL
system	NULL
before	NULL
CD4*	NULL
T	NULL
helper	NULL
cell	NULL
depletion	NULL
occurs	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

82:1908.	NULL
.	NULL

Fauci	NULL
,	NULL
A.	NULL
S.	NULL
,	NULL
G.	NULL
Pantaleo	NULL
,	NULL
S.	NULL
Stanley	NULL
,	NULL
and	NULL
D.	NULL
Weissman	NULL
.	NULL

1996	NULL
.	NULL

Immunopathogenic	NULL
mechanisms	NULL
of	NULL
HIV	NULL
infection	NULL
.	NULL

Ann	NULL
.	NULL

Intern	NULL
.	NULL

Med	NULL
.	NULL

124:654.	NULL
.	NULL

Cayota	NULL
,	NULL
A.	NULL
,	NULL
F.	NULL
Vuillier	NULL
,	NULL
J.	NULL
Siciliano	NULL
,	NULL
and	NULL
G.	NULL
Dighiero	NULL
.	NULL

1994	NULL
.	NULL

Defective	NULL
protein	NULL
tyrosine	NULL
phosphorylation	NULL
and	NULL
altered	NULL
levels	NULL
of	NULL
p59	NULL
``	NULL
and	NULL
p56	NULL
``	NULL
**	NULL
in	NULL
CD4	NULL
T	NULL
cells	NULL
from	NULL
HIV-1	NULL
infected	NULL
patients	NULL
.	NULL

Int	NULL
.	NULL

Immunol	NULL
.	NULL

6:611.	NULL
.	NULL

Kanner	NULL
,	NULL
S.	NULL
B.	NULL
,	NULL
and	NULL
O.	NULL
K.	NULL
Haffar	NULL
.	NULL

1995	NULL
.	NULL

HIV-1	NULL
down-regulates	NULL
CD4	NULL
costimulation	NULL
of	NULL
TCR/CD3-directed	NULL
tyrosine	NULL
phosphorylation	NULL
through	NULL
CD4/p56	NULL
``	NULL
**	NULL
dissociation	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

154:2996.	NULL
.	NULL

Guntermann	NULL
,	NULL
C.	NULL
,	NULL
J.	NULL
Dye	NULL
,	NULL
and	NULL
K.	NULL
E.	NULL
Nye	NULL
.	NULL

1997	NULL
.	NULL

Human	NULL
immunodeficiency	NULL
virus	NULL
infection	NULL
abolishes	NULL
CD4-dependent	NULL
activation	NULL
of	NULL
ZAP-70	NULL
by	NULL
inhibition	NULL
of	NULL
p56	NULL
``	NULL
**	NULL
.	NULL

J	NULL
.	NULL

Acquired	NULL
Immune	NULL
Defic	NULL
.	NULL

Syndr	NULL
.	NULL

Hum	NULL
.	NULL

Retrovirol	NULL
.	NULL

14:204.	NULL
.	NULL

Morio	NULL
,	NULL
T.	NULL
,	NULL
T.	NULL
Chatila	NULL
,	NULL
and	NULL
R.	NULL
S.	NULL
Geha	NULL
.	NULL

1997	NULL
.	NULL

HIV	NULL
glycoprotein	NULL
gp120	NULL
inhibits	NULL
TCR-CD3-mediated	NULL
activation	NULL
of	NULL
fyn	NULL
and	NULL
Ick	NULL
.	NULL

Int	NULL
.	NULL

Immunol	NULL
.	NULL

9:53.	NULL
.	NULL

Phipps	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
S.	NULL
E.	NULL
Read	NULL
,	NULL
J.	NULL
P.	NULL
Piovesan	NULL
,	NULL
G.	NULL
B	NULL
.	NULL

Mills	NULL
,	NULL
and	NULL
D.	NULL
R.	NULL
Branch	NULL
.	NULL

1996	NULL
.	NULL

HIV	NULL
infection	NULL
in	NULL
vitro	NULL
enhances	NULL
the	NULL
activity	NULL
of	NULL
src-family	NULL
protein	NULL
tyrosine	NULL
kinases	NULL
.	NULL

AIDS	NULL
10:1191.	NULL
.	NULL

Cayota	NULL
,	NULL
A.	NULL
,	NULL
F.	NULL
Vuillier	NULL
,	NULL
G.	NULL
Gonzalez	NULL
,	NULL
and	NULL
G.	NULL
Dighiero	NULL
.	NULL

1996	NULL
.	NULL

CD4*	NULL
lymphocytes	NULL
from	NULL
HIV-infected	NULL
patients	NULL
display	NULL
impaired	NULL
CD45-	NULL
associated	NULL
tyrosine	NULL
phosphatase	NULL
activity	NULL
which	NULL
is	NULL
enhanced	NULL
by	NULL
anti-	NULL
oxidants	NULL
.	NULL

Clin	NULL
.	NULL

Exp	NULL
.	NULL

Immunol	NULL
.	NULL

104:11.	NULL
.	NULL

Nokta	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
M.	NULL
I.	NULL
Hassan	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Morgan	NULL
,	NULL
K.	NULL
A.	NULL
Loesch	NULL
,	NULL
and	NULL
R.	NULL
B.	NULL
Pollard	NULL
.	NULL

1994	NULL
.	NULL

Protein	NULL
kinase	NULL
C	NULL
and	NULL
intracellular	NULL
free	NULL
Ca++	NULL
:	NULL
relationship	NULL
to	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
(	NULL
HIV	NULL
)	NULL
-induced	NULL
cellular	NULL
hyporesponsiveness	NULL
.	NULL

Proc	NULL
.	NULL

Soc	NULL
.	NULL

Exp	NULL
.	NULL

Biol	NULL
.	NULL

Med	NULL
.	NULL

207:284	NULL
.	NULL

Jabado	NULL
,	NULL
N.	NULL
,	NULL
A.	NULL
Pallier	NULL
,	NULL
S.	NULL
Jauliac	NULL
,	NULL
A.	NULL
Fischer	NULL
,	NULL
and	NULL
C.	NULL
Hivroz	NULL
.	NULL

1997.	NULL
gp160	NULL
of	NULL
HIV	NULL
or	NULL
anti-CD4	NULL
monoclonal	NULL
antibody	NULL
ligation	NULL
of	NULL
CD4	NULL
induces	NULL
inhibition	NULL
of	NULL
JNK	NULL
and	NULL
ERK-2	NULL
activities	NULL
in	NULL
human	NULL
peripheral	NULL
CD4	NULL
*	NULL
T	NULL
lymphocytes	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

27:397	NULL
.	NULL

Clerici	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
G.	NULL
M.	NULL
Shearer	NULL
.	NULL

1994	NULL
.	NULL

The	NULL
Th1-Th2	NULL
hypothesis	NULL
of	NULL
HIV	NULL
infection	NULL
:	NULL
new	NULL
insights	NULL
.	NULL

Immunol	NULL
.	NULL

Today	NULL
15:575	NULL
.	NULL

Romagnani	NULL
,	NULL
S.	NULL
1996	NULL
.	NULL

Understanding	NULL
the	NULL
role	NULL
of	NULL
Th1/Th2	NULL
cells	NULL
in	NULL
infection	NULL
.	NULL

Trends	NULL
Microbiol	NULL
.	NULL

4:470	NULL
.	NULL

Klein	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
J.	NULL
M.	NULL
Dobmeyer	NULL
,	NULL
T.	NULL
S.	NULL
Dobmeyer	NULL
,	NULL
M.	NULL
Pape	NULL
,	NULL
O.	NULL
G.	NULL
Ottmann	NULL
,	NULL
E.	NULL
B	NULL
.	NULL

Helm	NULL
,	NULL
D.	NULL
Hoelzer	NULL
,	NULL
and	NULL
R.	NULL
Rossol	NULL
.	NULL

1997	NULL
.	NULL

Demonstration	NULL
of	NULL
the	NULL
Th1	NULL
to	NULL
Th2	NULL
cytokine	NULL
shift	NULL
during	NULL
the	NULL
course	NULL
of	NULL
HIV-	NULL
1	NULL
infection	NULL
using	NULL
cytoplasmic	NULL
cytokine	NULL
detection	NULL
on	NULL
single	NULL
cell	NULL
level	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

AIDS	NULL
17:1111	NULL
.	NULL

O'Shea	NULL
,	NULL
J.	NULL
J	NULL
.	NULL

1997	NULL
.	NULL

Jaks	NULL
,	NULL
STATs	NULL
,	NULL
cytokine	NULL
signal	NULL
transduction	NULL
,	NULL
and	NULL
immunoregu-lation	NULL
:	NULL
are	NULL
we	NULL
there	NULL
yet	NULL
?	NULL

Immunity	NULL
7:1	NULL
.	NULL

Thile	NULL
,	NULL
J.	NULL
N.	NULL
1996	NULL
.	NULL

STATs	NULL
:	NULL
signal	NULL
transducers	NULL
and	NULL
activators	NULL
of	NULL
transcription	NULL
.	NULL

Cell	NULL
84:331	NULL
.	NULL

Darnell	NULL
,	NULL
J.	NULL
E.	NULL
1997	NULL
.	NULL

STATs	NULL
and	NULL
gene	NULL
regulation	NULL
.	NULL

Science	NULL
277:1630	NULL
.	NULL

Liu	NULL
,	NULL
X.	NULL
,	NULL
G.	NULL
W.	NULL
Robinson	NULL
,	NULL
F.	NULL
Gouilleux	NULL
,	NULL
B.	NULL
Groner	NULL
,	NULL
and	NULL
L.	NULL
Hennighausen	NULL
.	NULL

1995	NULL
.	NULL

Cloning	NULL
and	NULL
expression	NULL
of	NULL
Stat5	NULL
and	NULL
an	NULL
additional	NULL
homologue	NULL
(	NULL
StatSb	NULL
)	NULL
involved	NULL
in	NULL
prolactin	NULL
signal	NULL
transduction	NULL
in	NULL
mouse	NULL
mammary	NULL
tissue	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
92:8831	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

31	NULL
Heim	NULL
,	NULL
M.	NULL
H.	NULL
1996	NULL
.	NULL

The	NULL
Jak-STAT	NULL
pathway	NULL
:	NULL
specific	NULL
signal	NULL
transduction	NULL
from	NULL
the	NULL
cell	NULL
membrane	NULL
to	NULL
the	NULL
nucleus	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

26:1	NULL
.	NULL

Pericle	NULL
,	NULL
F.	NULL
,	NULL
R.	NULL
A.	NULL
Kirken	NULL
,	NULL
V.	NULL
Bronte	NULL
,	NULL
G.	NULL
Sconocchia	NULL
,	NULL
L.	NULL
DaSilva	NULL
,	NULL
and	NULL
D.	NULL
M.	NULL
Segal	NULL
.	NULL

1997	NULL
.	NULL

Immunocompromised	NULL
tumor-bearing	NULL
mice	NULL
show	NULL
a	NULL
selective	NULL
loss	NULL
of	NULL
STATS5	NULL
@	NULL
/b	NULL
expression	NULL
in	NULL
T	NULL
and	NULL
B	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

159:2580	NULL
.	NULL

Pinto	NULL
,	NULL
L.	NULL
A.	NULL
,	NULL
J.	NULL
Sullivan	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Berzofsky	NULL
,	NULL
M.	NULL
Clerici	NULL
,	NULL
H.	NULL
A.	NULL
Kessler	NULL
,	NULL
A.	NULL
L.	NULL
Landay	NULL
,	NULL
and	NULL
G.	NULL
M.	NULL
Shearer	NULL
.	NULL

1995	NULL
.	NULL

ENV-specific	NULL
cytotoxic	NULL
T	NULL
lymphocyte	NULL
responses	NULL
in	NULL
HIV	NULL
seronegative	NULL
health	NULL
care	NULL
workers	NULL
occupationally	NULL
exposed	NULL
to	NULL
HIV-contaminated	NULL
body	NULL
fluids	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

96:867	NULL
.	NULL

Blauvelt	NULL
,	NULL
A.	NULL
,	NULL
M.	NULL
Clerici	NULL
,	NULL
D.	NULL
R.	NULL
Lucey	NULL
,	NULL
S.	NULL
M.	NULL
Steinberg	NULL
,	NULL
R.	NULL
Yarchoan	NULL
,	NULL
R.	NULL
Walker	NULL
,	NULL
G.	NULL
M.	NULL
Shearer	NULL
,	NULL
and	NULL
S.	NULL
I.	NULL
Katz	NULL
.	NULL

1995	NULL
.	NULL

Functional	NULL
studies	NULL
of	NULL
epidermal	NULL
Langerhans	NULL
cells	NULL
and	NULL
blood	NULL
monocytes	NULL
in	NULL
HIV-infected	NULL
persons	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

154:3506	NULL
.	NULL

Redfield	NULL
,	NULL
R.	NULL
R.	NULL
,	NULL
D.	NULL
C.	NULL
Wright	NULL
,	NULL
and	NULL
E.	NULL
C.	NULL
Tramont	NULL
.	NULL

1986	NULL
.	NULL

The	NULL
Walter	NULL
Reed	NULL
staging	NULL
classification	NULL
for	NULL
HTLV-III/LAYV	NULL
infection	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

314:131	NULL
.	NULL

Zolla-Pazner	NULL
,	NULL
S.	NULL
,	NULL
J.	NULL
O'Leary	NULL
,	NULL
S.	NULL
Burda	NULL
,	NULL
M.	NULL
K.	NULL
Gomy	NULL
,	NULL
M.	NULL
Kim	NULL
,	NULL
J.	NULL
Mascola	NULL
,	NULL
and	NULL
F.	NULL
McCutchan	NULL
.	NULL

1995	NULL
.	NULL

Serotyping	NULL
of	NULL
primary	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
isolates	NULL
from	NULL
diverse	NULL
geographic	NULL
locations	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

69:3807	NULL
.	NULL

Sakaida	NULL
,	NULL
H.	NULL
,	NULL
T.	NULL
Murakami	NULL
,	NULL
S.	NULL
Kawamata	NULL
,	NULL
T.	NULL
Hattori	NULL
,	NULL
and	NULL
T.	NULL
Uchiyama	NULL
.	NULL

1997	NULL
.	NULL

V3	NULL
loop	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
suppresses	NULL
interleukin	NULL
2-induced	NULL
T	NULL
cell	NULL
growth	NULL
.	NULL

AIDS	NULL
Res	NULL
.	NULL

Hum	NULL
.	NULL

Retroviruses	NULL
13:151	NULL
.	NULL

Chirmule	NULL
,	NULL
N.	NULL
,	NULL
and	NULL
S.	NULL
Pahwa	NULL
.	NULL

1996	NULL
.	NULL

Envelope	NULL
glycoproteins	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
:	NULL
profound	NULL
influences	NULL
on	NULL
immune	NULL
functions	NULL
.	NULL

Microbiol	NULL
.	NULL

Rev	NULL
.	NULL

60:386	NULL
.	NULL

Purvis	NULL
,	NULL
S.	NULL
F.	NULL
,	NULL
D.	NULL
L.	NULL
Georges	NULL
,	NULL
T.	NULL
M.	NULL
Williams	NULL
,	NULL
and	NULL
M.	NULL
M.	NULL
Lederman	NULL
.	NULL

1992	NULL
.	NULL

Suppression	NULL
of	NULL
interleukin-2	NULL
and	NULL
interleukin-2	NULL
receptor	NULL
expression	NULL
in	NULL
Jurkat	NULL
cells	NULL
stably	NULL
expressing	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
Tat	NULL
protein	NULL
.	NULL

Cell	NULL
.	NULL

Immunol	NULL
.	NULL

144:32	NULL
.	NULL

Blazevic	NULL
,	NULL
V.	NULL
,	NULL
M.	NULL
Heino	NULL
,	NULL
A.	NULL
Lagerstedt	NULL
,	NULL
A.	NULL
Ranki	NULL
,	NULL
and	NULL
K.	NULL
J.	NULL
Krohn	NULL
.	NULL

1996	NULL
.	NULL

Inter-leukin-10	NULL
gene	NULL
expression	NULL
induced	NULL
by	NULL
HIV-1	NULL
Tat	NULL
and	NULL
Rev	NULL
in	NULL
the	NULL
cells	NULL
of	NULL
HIV-1	NULL
infected	NULL
individuals	NULL
.	NULL

J	NULL
.	NULL

Acquired	NULL
Immune	NULL
Defic	NULL
.	NULL

Syndr	NULL
.	NULL

Hum	NULL
.	NULL

Retrovirol	NULL
.	NULL

13:208	NULL
.	NULL

Deng	NULL
,	NULL
H.	NULL
,	NULL
R.	NULL
Liu	NULL
,	NULL
W.	NULL
Ellimeier	NULL
,	NULL
S.	NULL
Choe	NULL
,	NULL
D.	NULL
Unutmaz	NULL
,	NULL
M.	NULL
Burkhart	NULL
,	NULL
P.	NULL
Di	NULL
Marzio	NULL
,	NULL
S.	NULL
Marmon	NULL
,	NULL
R.	NULL
E.	NULL
Sutton	NULL
,	NULL
C.	NULL
M.	NULL
Hill	NULL
,	NULL
C.	NULL
B.	NULL
Davis	NULL
,	NULL
S.	NULL
C.	NULL
Peiper	NULL
,	NULL
T.	NULL
J.	NULL
Schall	NULL
,	NULL
D.	NULL
R.	NULL
Littman	NULL
,	NULL
and	NULL
N.	NULL
R.	NULL
Landau	NULL
.	NULL

1996	NULL
.	NULL

Identification	NULL
of	NULL
a	NULL
major	NULL
co-receptor	NULL
for	NULL
primary	NULL
isolates	NULL
of	NULL
HIV-1	NULL
.	NULL

Nature	NULL
381:661	NULL
.	NULL

Moore	NULL
,	NULL
J.	NULL
P.	NULL
1997	NULL
.	NULL

Coreceptors	NULL
:	NULL
implications	NULL
for	NULL
HIV	NULL
pathogenesis	NULL
and	NULL
therapy	NULL
.	NULL

Science	NULL
276:51.	NULL
va	NULL
n't	NULL
Wout	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
,	NULL
N.	NULL
A.	NULL
Kootstra	NULL
,	NULL
G.	NULL
A.	NULL
Mulder-Kampinga	NULL
,	NULL
N.	NULL
Albrecht-van	NULL
Lent	NULL
,	NULL
H.	NULL
J.	NULL
Scherpbier	NULL
,	NULL
J.	NULL
Veensira	NULL
,	NULL
K.	NULL
Boer	NULL
,	NULL
R.	NULL
A.	NULL
Coutinho	NULL
,	NULL
F.	NULL
Micdema	NULL
,	NULL
and	NULL
H.	NULL
Schuitemaker	NULL
.	NULL

1994	NULL
.	NULL

Macrophage-tropic	NULL
variants	NULL
initiate	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
infection	NULL
after	NULL
sexual	NULL
,	NULL
parenteral	NULL
,	NULL
and	NULL
vertical	NULL
transmission	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

94:2060	NULL
.	NULL

Rosenberg	NULL
,	NULL
Z.	NULL
F.	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Fauci	NULL
.	NULL

1993	NULL
.	NULL

Immunology	NULL
of	NULL
HIV	NULL
infection	NULL
.	NULL

In	NULL
Fundamental	NULL
Immunology	NULL
,	NULL
3rd	NULL
ed	NULL
.	NULL

W.	NULL
E.	NULL
Paul	NULL
,	NULL
ed	NULL
.	NULL

Raven	NULL
Press	NULL
,	NULL
Ltd	NULL
,	NULL
New	NULL
York	NULL
,	NULL
p.	NULL
1375	NULL
.	NULL

6107	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
810	NULL
wor	NULL
;	NULL

